Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CollPlant BiotechnologiesFRA:CPT 44 12-1 Month Momentum % is -87.57% as of Sep. 06, 2026. GuruFocus rates FRA:CPT with a GF Score™ of 44/100 and a GF Value™ of €2.34 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,359 Biotechnology companies, CollPlant Biotechnologies ranks worse than 95.95% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-09-06), CollPlant Biotechnologies's 12-1 Month Momentum % is -87.57%.
The industry rank for CollPlant Biotechnologies's 12-1 Month Momentum % or its related term are showing as below:
FRA:CPT's 12-1 Month Momentum % is ranked worse than 95.95% of 1359
companies
in the Biotechnology industry
Industry Median: -21.19
vs FRA:CPT: -87.57
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
CollPlant Biotechnologies 12-1 Month Momentum % Related Terms
FRA:CPT vs DRMA, AAGH, HCWB: 12-1 Month Momentum % Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies 12-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -87.57% mean?
CollPlant Biotechnologies (FRA:CPT) has a 12-1 Month Momentum % of -87.57% as of Sep. 06, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #1304 out of 1359 companies in the Biotechnology industry, placing it in the top 96%.
Is CollPlant Biotechnologies' 12-1 Month Momentum % too high?
CollPlant Biotechnologies' current 12-1 Month Momentum % is -87.57%. Based on the distribution chart, CollPlant Biotechnologies ranks #1304 out of 1359 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CollPlant Biotechnologies has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' 12-1 Month Momentum % compare to DRMA and AAGH?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #1304 out of 1359 companies for 12-1 Month Momentum %. This places CollPlant Biotechnologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Biotechnology company?
A good 12-1 Month Momentum % depends on the Biotechnology industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on CollPlant Biotechnologies and its competitors. CollPlant Biotechnologies's current 12-1 Month Momentum % is -87.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (FRA:CPT) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.34, compared to a current price of €3.50 — trading 49.6% above its estimated fair value. The current 12-1 Month Momentum % is -87.57%. CollPlant Biotechnologies' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For CollPlant Biotechnologies (FRA:CPT), the current 12-1 Month Momentum % is -87.57% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (FRA:CPT) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of €3.50 is trading 49.6% above its estimated GF Value™ of €2.34.
GuruFocus considers CollPlant Biotechnologies to be Significantly Overvalued.
Key valuation signals for FRA:CPT:
12-1 Month Momentum %: -87.57%
GF Value™: €2.34 vs. price of €3.50 (49.6% above fair value)
No single metric tells the full story. See the FRA:CPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
44GF Score
Get the complete analysis for FRA:CPT
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CPT has been successfully added to your 
